Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Peter Noertersheuser"'
Autor:
Denise Beck, Insa Winzenborg, Wei Gao, Nael M. Mostafa, Peter Noertersheuser, Stephanie E. Chiuve, Charlotte Owens, Mohamad Shebley
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1452-1463 (2021)
Abstract Decline of bone mineral density (BMD) during menopause is related to increased risk of fractures in postmenopausal women, however, this relationship in premenopausal women has not been established. To quantify this relationship, real‐world
Externí odkaz:
https://doaj.org/article/668fcd1e2bf94365ac22a86e6bc82dc7
Autor:
Sven Stodtmann, Ahmed Nader, Akshanth R. Polepally, Ahmed A. Suleiman, Insa Winzenborg, Peter Noertersheuser, Juki Ng, Nael M. Mostafa, Mohamad Shebley
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1611-1619 (2021)
Abstract Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent wi
Externí odkaz:
https://doaj.org/article/bdc368c4a22d4730855a7980b67fdb9e
Autor:
Ahmed Abbas Suleiman, Ahmed Nader, Insa Winzenborg, Denise Beck, Akshanth R. Polepally, Juki Ng, Peter Noertersheuser, Nael M. Mostafa
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 11, Pp 639-648 (2020)
Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population exposure
Externí odkaz:
https://doaj.org/article/e1f1aa1ff5ef41e1bc9e699636ed3364
Autor:
Insa Winzenborg, Akshanth R. Polepally, Ahmed Nader, Nael M. Mostafa, Peter Noertersheuser, Juki Ng
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 8, Pp 466-475 (2020)
Elagolix is an oral gonadotropin‐releasing hormone antagonist approved by the US Food and Drug Administration (FDA) for the management of moderate‐to‐severe pain associated with endometriosis and in combination with estradiol/norethindrone acet
Externí odkaz:
https://doaj.org/article/ca175fc97311409e9f23f71e5d2e5314
Autor:
Juki Ng, Akshanth R. Polepally, Sven Stodtmann, Nael M. Mostafa, Peter Noertersheuser, Mohamad Shebley, Ahmed Nader, Insa Winzenborg, Ahmed Abbas Suleiman
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1611-1619 (2021)
Clinical and Translational Science, Vol 14, Iss 4, Pp 1611-1619 (2021)
Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent with its me
Autor:
Charlotte D. Owens, Wei Gao, Denise Beck, Nael M. Mostafa, Stephanie E Chiuve, Mohamad Shebley, Insa Winzenborg, Peter Noertersheuser
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1452-1463 (2021)
Clinical and Translational Science, Vol 14, Iss 4, Pp 1452-1463 (2021)
Decline of bone mineral density (BMD) during menopause is related to increased risk of fractures in postmenopausal women, however, this relationship in premenopausal women has not been established. To quantify this relationship, real‐world data (RW
Autor:
Akshanth R. Polepally, Ahmed Nader, Ahmed Abbas Suleiman, Denise Beck, Juki Ng, Peter Noertersheuser, Nael M. Mostafa, Insa Winzenborg
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 11, Pp 639-648 (2020)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose-dependent manner. It is indicated for management of moderate-to-severe pain associated with endometriosis. A population exposure-respon
Autor:
Juki Ng, Ahmed Nader, Mohamad Shebley, Peter Noertersheuser, Megan A. Gibbs, Cheri E. Klein, Akshanth R. Polepally, Insa Winzenborg, Nael M. Mostafa
Publikováno v:
Clinical Pharmacokinetics
The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affected by pa
Autor:
Ahmed A. Othman, Insa Winzenborg, Mohamed-Eslam F. Mohamed, Peter Noertersheuser, Eva Doelger, Ahmed Nader, Aileen L. Pangan
Publikováno v:
Clinical Pharmacology and Therapeutics
Exposure–response analyses of upadacitinib (UPA) key efficacy and safety end points (3,685 and 4,577 subjects for efficacy and safety, respectively) using data from phase II and phase III rheumatoid arthritis (RA) studies were conducted to support
Autor:
Denise Beck, Insa Winzenborg, Mohan Liu, Jacob Degner, Nael M. Mostafa, Peter Noertersheuser, Mohamad Shebley
Publikováno v:
Clinical pharmacokinetics. 61(4)
Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and fact